Healthcare Sector

LIFE

Market Tracker

$13.69
-1.36
(-9.04%)
5:20 am
Next Earnings: (est.) 08/16/23 12:00 am
  • LIFE (Selected)

    aTyr Pharma, Inc.

LIFE Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

LIFE Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

LIFE Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

LIFE Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

LIFE Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

LIFE Major Holders

Name Pct Held Shares Total
Federated Hermes Kaufmann Small Cap Fund 5.46% 2.9M 5.8M
Federated Hermes Kaufmann Fund 4.26% 2.27M 4.53M
Fidelity Select Portfolios - Biotechnology 4.25% 2.26M 4.52M
Fidelity Growth Company Fund 3.35% 1.78M 3.56M
Vanguard Total Stock Market Index Fund 1.39% 737.93k 1.48M
Fidelity Growth Company K6 Fund 1.15% 609.7k 1.22M
Fidelity Series Growth Company Fund 0.89% 470.83k 941.66k
Vanguard Extended Market Index Fund 0.66% 353.29k 706.57k
Fidelity Extended Market Index Fund 0.27% 142.68k 285.35k
DFA U.S. Small Cap Series 0.18% 97.54k 195.08k

LIFE News

  • aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

    06/03 08:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    05/24 04:00 pm

    GlobeNewswire Inc.

    Read more
  • Wall Street Breakfast: The Week Ahead

    05/19 06:35 am

    Seeking Alpha

    Read more
  • aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference

    05/15 07:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

    05/14 08:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

    05/02 04:00 pm

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma to Participate in April Investor Conferences

    04/01 08:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    03/14 04:00 pm

    GlobeNewswire Inc.

    Read more
  • Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

    02/28 09:10 am

    Zacks Investment Research

    Read more
  • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

    02/28 09:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

    11/13 09:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

    11/09 05:00 pm

    GlobeNewswire Inc.

    Read more
  • Analyst Expectations for aTyr Pharma's Future

    09/21 12:00 pm

    Benzinga

    Read more
  • aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

    09/11 08:00 am

    GlobeNewswire Inc.

    Read more
  • 5 Top Stocks to Play Earnings Beat Potential

    09/04 07:30 am

    Zacks Investment Research

    Read more
  • Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)

    08/30 09:35 am

    Zacks Investment Research

    Read more
  • aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    08/24 08:00 am

    GlobeNewswire Inc.

    Read more
  • 5 Top Stocks Likely to Top Earnings Estimates

    08/18 07:49 am

    Zacks Investment Research

    Read more
  • Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates

    08/09 05:30 pm

    Zacks Investment Research

    Read more
  • aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

    08/09 04:00 pm

    GlobeNewswire Inc.

    Read more
  • $12M Bet On This Trucking Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

    08/02 09:06 am

    Benzinga

    Read more
  • aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst

    07/05 03:35 pm

    Benzinga

    Read more
  • Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023

    07/05 11:02 am

    Benzinga

    Read more
  • aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

    06/20 08:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    06/09 04:00 pm

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

    05/25 08:00 am

    GlobeNewswire Inc.

    Read more
  • The Latest Analyst Ratings for aTyr Pharma

    05/23 04:01 pm

    Benzinga

    Read more
  • Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

    05/09 05:15 pm

    Zacks Investment Research

    Read more
  • Where aTyr Pharma Stands With Analysts

    03/10 11:01 am

    Benzinga

    Read more
  • Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates

    03/09 06:15 pm

    Zacks Investment Research

    Read more
  • aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

    03/09 05:00 pm

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma to Present at March Investor Conferences

    03/08 09:00 am

    GlobeNewswire Inc.

    Read more
  • Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know

    02/17 01:00 pm

    Zacks Investment Research

    Read more
  • aTyr Pharma Announces Commencement of Public Offering of Common Stock

    02/08 05:11 pm

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    11/18 05:00 pm

    GlobeNewswire Inc.

    Read more
  • Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates

    11/10 06:15 pm

    Zacks Investment Research

    Read more
  • aTyr Pharma to Present at Upcoming Investor Conferences

    11/10 09:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

    11/03 08:02 am

    GlobeNewswire Inc.

    Read more
  • NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks

    08/16 07:49 am

    Benzinga

    Read more
  • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    08/12 04:05 pm

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

    08/11 08:03 am

    GlobeNewswire Inc.

    Read more
  • Best Penny Stocks to Buy Now According To 3 Top Analysts

    07/21 11:59 am

    PennyStocks

    Read more
  • Snap to $25? Plus This Analyst Cuts Price Target On Amazon.com

    07/21 08:43 am

    Benzinga

    Read more
  • $1.4 Million Bet On This Healthcare Stock? 4 Penny Stocks Insiders are Buying

    07/07 08:16 am

    Benzinga

    Read more
  • aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

    06/14 08:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    05/13 04:00 pm

    GlobeNewswire Inc.

    Read more
  • Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

    05/09 05:15 pm

    Zacks Investment Research

    Read more
  • aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod

    04/14 12:14 pm

    Zacks Investment Research

    Read more
  • aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis

    04/13 08:00 am

    GlobeNewswire Inc.

    Read more
  • aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

    04/01 08:00 am

    GlobeNewswire Inc.

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: